A Comparative Study of the ReCell Device and Autologous Spit-thickness Meshed Skin Graft in the Treatment of Acute Burn Injuries.

MedStar author(s):
Citation: Journal of Burn Care & Research. 39(5):694-702, 2018 08 17.PMID: 29800234Institution: MedStar Washington Hospital CenterDepartment: Surgery/Burn ServicesForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Burns/su [Surgery] | *Skin Transplantation | *Tissue and Organ Harvesting/is [Instrumentation] | Adolescent | Adult | Female | Humans | Male | Middle Aged | Prospective Studies | Surgical Mesh | Transplantation, Autologous | Treatment Outcome | Wound Healing | Young AdultYear: 2018Local holdings: Available online through MWHC library: 2006 - present, Available in print through MWHC library: 2006 - presentISSN:
  • 1559-047X
Name of journal: Journal of burn care & research : official publication of the American Burn AssociationAbstract: Conclusions: This study provides evidence that the treatment of DPT burns with ASCS results in comparable healing, with significantly reduced donor site size and pain and improved appearance relative to STSG.Introduction: Early excision and autografting are standard care for deeper burns. However, donor sites are a source of significant morbidity. To address this, the ReCell Autologous Cell Harvesting Device (ReCell) was designed for use at the point-of-care to prepare a non-cultured, autologous skin cell suspension (ASCS) capable of epidermal regeneration utilizing minimal donor skin.Methods: A prospective study was conducted to evaluate the clinical performance of ReCell versus meshed split-thickness skin grafts (STSG, Control) for the treatment of deep partial-thickness (DPT) burns. Effectiveness measures were assessed to 1 year for both ASCS and Control treatment sites and donor sites, including the incidence of healing, scarring, and pain.Results: At 4 weeks, 98% of the ASCS-treated sites were healed compared to 100% of the Controls. Pain and assessments of scarring at the treatment sites were reported to be similar between groups. Significant differences were observed between ReCell and Control donor sites. The mean ReCell donor area was approximately 40 times smaller than that of the Control (194.1+/-158.5 cm2; p<0.0001), and after 1 week, significantly more ReCell donor sites were healed than Controls (p=0.04). Over the first 16 weeks, patients reported significantly less pain at the ReCell donor sites compared with Controls (p<=0.05 at each time point). Long-term, patients reported higher satisfaction with ReCell donor site outcomes compared with the Controls.All authors: Cairns BA, Carter JE, Cruse CW, Dissanaike S, Feldman MJ, Foster KN, Greenhalgh DG, Griswold JA, Hickerson WL, Holmes JH 4th, Hwang J, Jordan MH, King BT, Molnar JA, Mozingo DW, Palmieri TL, Peck MD, Smith DJ, Sood ROriginally published: Journal of Burn Care & Research. 2018 May 24Fiscal year: FY2018Digital Object Identifier: Date added to catalog: 2018-06-19
Holdings
Item type Current library Collection Call number Status Date due Barcode
Journal Article MedStar Authors Catalog Article 29800234 Available 29800234

Available online through MWHC library: 2006 - present, Available in print through MWHC library: 2006 - present

Conclusions: This study provides evidence that the treatment of DPT burns with ASCS results in comparable healing, with significantly reduced donor site size and pain and improved appearance relative to STSG.

Introduction: Early excision and autografting are standard care for deeper burns. However, donor sites are a source of significant morbidity. To address this, the ReCell Autologous Cell Harvesting Device (ReCell) was designed for use at the point-of-care to prepare a non-cultured, autologous skin cell suspension (ASCS) capable of epidermal regeneration utilizing minimal donor skin.

Methods: A prospective study was conducted to evaluate the clinical performance of ReCell versus meshed split-thickness skin grafts (STSG, Control) for the treatment of deep partial-thickness (DPT) burns. Effectiveness measures were assessed to 1 year for both ASCS and Control treatment sites and donor sites, including the incidence of healing, scarring, and pain.

Results: At 4 weeks, 98% of the ASCS-treated sites were healed compared to 100% of the Controls. Pain and assessments of scarring at the treatment sites were reported to be similar between groups. Significant differences were observed between ReCell and Control donor sites. The mean ReCell donor area was approximately 40 times smaller than that of the Control (194.1+/-158.5 cm2; p<0.0001), and after 1 week, significantly more ReCell donor sites were healed than Controls (p=0.04). Over the first 16 weeks, patients reported significantly less pain at the ReCell donor sites compared with Controls (p<=0.05 at each time point). Long-term, patients reported higher satisfaction with ReCell donor site outcomes compared with the Controls.

English

Powered by Koha